Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.

Maus MV, Plotkin J, Jakka G, Stewart-Jones G, Rivière I, Merghoub T, Wolchok J, Renner C, Sadelain M.

Mol Ther Oncolytics. 2017 Jan 11;3:1-9. doi: 10.1038/mto.2016.23. eCollection 2016.

2.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):985-94. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.

3.
4.

Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y.

J Immunol. 2014 Dec 1;193(11):5733-43. doi: 10.4049/jimmunol.1301769. Epub 2014 Oct 31.

5.

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.

Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA.

J Immunol. 2005 Apr 1;174(7):4415-23.

6.

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A.

J Exp Med. 1998 Jan 19;187(2):265-70.

7.

Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.

Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A, Tsujikawa J, Demachi-Okamura A, Hiramatsu K, Saji H, Yamamoto Y, Yamamoto N, Nishimura Y, Takahashi T, Kuzushima K, Emi N, Akatsuka Y.

Gene Ther. 2014 Jun;21(6):575-84. doi: 10.1038/gt.2014.30. Epub 2014 Apr 3.

PMID:
24694533
8.
10.

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK.

Cancer Immunol Immunother. 2013 Apr;62(4):773-85. doi: 10.1007/s00262-012-1384-4. Epub 2012 Dec 22.

11.

Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.

Jakka G, Schuberth PC, Thiel M, Held G, Stenner F, Van Den Broek M, Renner C, Mischo A, Petrausch U.

Anticancer Res. 2013 Oct;33(10):4189-201.

PMID:
24122982
12.

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.

Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr.

Oncotarget. 2015 Aug 28;6(25):21533-46.

13.

Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.

Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10702-E10711. doi: 10.1073/pnas.1810653115. Epub 2018 Oct 22.

14.

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O'Reilly RJ, Cheung NK.

Leukemia. 2015 Nov;29(11):2238-47. doi: 10.1038/leu.2015.125. Epub 2015 May 19.

15.

Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.

Krönig H, Hofer K, Conrad H, Guilaume P, Müller J, Schiemann M, Lennerz V, Cosma A, Peschel C, Busch DH, Romero P, Bernhard H.

Int J Cancer. 2009 Aug 1;125(3):649-55. doi: 10.1002/ijc.24414.

17.
20.

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.

Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C.

Eur J Immunol. 2004 Oct;34(10):2919-29.

Supplemental Content

Support Center